Table 5. The top ten significant Bio-Functions altered following Sox2 down-modulation in the GSC11 cell line.
| Category | p-value | Number of Targets |
|---|---|---|
| Dermatological Diseases and Conditions | 1,63 x 10−08–9,35 x 10−03 | 74 |
| Cancer | 2,93 x 10−08–9,35 x 10−03 | 93 |
| Organismal Injury and Abnormalities | 2,93 x 10−08–9,35 x 10−03 | 100 |
| Cellular Movement | 3,98 x 10−06–9,35 x 10−03 | 41 |
| Connective Tissue Development and Function | 1,71 x 10−05–9,35 x 10−03 | 23 |
| Tissue Morphology | 1,71 x 10−05–9,35 x 10−03 | 39 |
| Reproductive System Disease | 2,52 x 10−05–9,35 x 10−03 | 16 |
| Cellular Development | 2,72 x 10−05–9,35 x 10−03 | 51 |
| Hematological System Development and Function | 2,72 x 10−05–9,35 x 10−03 | 31 |
| Hematopoiesis | 2,72 x 10−05–9,35 x 10−03 | 9 |
The p-value range indicates the p-values of the various pathways and processes belonging to that category. The number of targets indicates the total number of genes associated with the functional category.